YOLFTbeta
Shenzhen Hepalink Pharmaceutical Co Ltd

Shenzhen Hepalink Pharmaceutical Co Ltd

002399 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

9.10CNY-0.15 (-1.62%)

Price History

Full chart

Market Stats

Previous Close9.25
Open9.26
Day Range9.05 – 9.26
52-Week Range8.50 – 12.48
Volume2.83M
Market Cap14.45B
P/E (TTM)70.36
Forward P/E24.04
EPS0.14
Dividend Yield1.51%
Beta0.28
50-Day Avg9.96
200-Day Avg10.74

About

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Li Li
  • Employees2.15K
  • HeadquartersNo. 21 Langshan Road, Shenzhen, China, 518057, China
  • Websitehttps://www.hepalink.com

Leadership

  • Mr. Li LiCo-Founder, Executive Chairman of the Board & President · b. 1964
  • Mr. Yu ShanCo-Founder, GM, Group VP & Executive Director · b. 1960
  • Ms. Tan LiCo-founder, VP, Deputy GM & Executive Director · b. 1964
  • Ms. Juan ChenVP of Finance, CFO & Financial Controller · b. 1975
  • Mr. Jianyi WangEmployee Representative Director & Director of Organization and HR · b. 1982

Financials

Income Statement

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue277.79M299.38M435.22M2.22B3.85B2.49B1.76B1.51B1.96B2.29B2.26B2.84B4.81B4.62B5.33B6.37B7.16B5.43B5.26B5.48B
Growth (%)-+7.77%+45.37%+411.03%+73.26%-35.26%-29.37%-14.11%+29.45%+17.02%-1.37%+25.76%+69.34%-3.95%+15.30%+19.38%+12.48%-24.14%-3.17%+4.18%
Cost of Revenue192.05M195.26M190.82M1.15B2.23B1.77B1.10B1.14B1.41B1.47B1.56B1.98B2.93B2.95B3.30B4.37B4.86B4.49B3.52B3.74B
Gross Profit85.75M104.12M244.40M1.07B1.62B720.04M664.95M373.21M547.00M818.50M697.51M862.95M1.88B1.68B2.03B2.00B2.30B940.90M1.74B1.74B
Gross Margin30.87%34.78%56.16%48.27%42.09%28.86%37.74%24.66%27.92%35.71%30.85%30.35%39.09%36.27%38.11%31.39%32.10%17.32%33.07%31.81%
Operating Expense33.81M30.93M46.50M98.89M205.15M148.74M175.99M224.80M156.82M174.60M261.90M770.72M1.19B362.72M701.97M1.77B1.47B1.38B1.23B1.11B
Operating Income51.94M73.19M197.89M974.77M1.42B571.31M488.96M148.42M390.18M643.90M435.61M92.22M692.48M1.31B1.33B227.47M828.62M-434.21M507.12M635.97M
Operating Margin18.70%24.45%45.47%43.83%36.76%22.90%27.75%9.81%19.92%28.09%19.27%3.24%14.38%28.43%24.94%3.57%11.57%-8.00%9.64%11.61%
EBITDA60.64M89.57M211.52M981.77M1.43B732.37M745.28M403.88M473.07M875.86M743.43M471.90M1.15B1.85B1.88B693.81M1.36B-366.74M1.16B846.59M
EBITDA Margin21.83%29.92%48.60%44.14%37.19%29.36%42.30%26.69%24.15%38.21%32.88%16.60%23.94%39.98%35.17%10.90%19.01%-6.75%22.07%15.45%
Net Income47.88M68.16M161.39M809.06M1.21B622.08M624.39M317.33M338.28M579.78M396.89M196.66M591.46M1.06B1.02B240.79M727.43M-783.26M646.74M349.49M
Net Income Margin17.24%22.77%37.08%36.38%31.39%24.94%35.44%20.97%17.27%25.29%17.55%6.92%12.28%22.91%19.21%3.78%10.16%-14.42%12.30%6.38%
R&D----158.56M25.53M30.09M39.97M59.46M97.17M62.05M93.54M186.53M148.71M160.01M221.10M252.14M182.43M212.04M226.16M
R&D as % of Total Revenue----4.11%1.02%1.71%2.64%3.04%4.24%2.74%3.29%3.87%3.22%3.00%3.47%3.52%3.36%4.03%4.13%
Interest Expense10.75M9.62M7.74M15.01M5.23M210.70K221.27K67.12K37.85M87.42M106.71M184.50M227.47M278.34M273.58M201.63M257.23M238.70M153.49M71.44M
Interest Expense % of Total Revenue3.87%3.21%1.78%0.67%0.14%0.01%0.01%0.00%1.93%3.81%4.72%6.49%4.72%6.02%5.13%3.17%3.59%4.40%2.92%1.30%

Balance Sheet

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets349.01M257.73M578.92M1.38B8.13B7.97B8.26B8.27B9.93B12.17B12.91B13.19B13.66B15.24B19.03B19.11B20.81B19.20B17.34B16.63B
Total Liabilities257.68M111.28M271.09M306.33M103.44M59.98M214.53M203.80M1.58B3.38B4.83B5.50B7.41B7.77B7.34B7.58B8.41B7.22B5.14B4.55B
Total Equity91.33M146.44M307.83M1.06B7.99B7.82B7.96B7.99B8.27B8.72B7.97B7.58B6.07B7.35B11.57B11.41B12.31B11.91B12.15B12.03B
Cash152.02M32.00M161.13M445.38M6.26B6.77B6.59B6.05B4.13B4.19B4.55B3.50B2.12B1.28B2.71B2.94B2.14B1.85B1.69B1.35B
Total Debt218.00M80.00M198.42M244.00M--73.16M-1.01B2.45B3.89B4.71B4.92B6.30B5.65B5.65B6.46B5.56B2.98B-
Net Debt65.98M48.00M37.29M-201.38M-6.26B-6.77B-6.52B-6.05B-3.12B-1.74B-662.78M1.21B2.79B5.02B2.93B2.71B4.33B1.93B1.29B722.40M

Cash Flow

Currency: CNY2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow71.66M13.85M40.13M355.81M354.86M1.41B473.89M420.97M912.80M893.71M346.07M-407.12M667.87M-227.60M37.28M-6.63M-756.61M398.22M2.19B1.71B
Investing Cash Flow-10.88M-11.43M-10.73M-54.91M-35.93M-141.21M-237.48M-406.64M-2.81B-1.66B-273.02M-1.21B-544.30M1.70M-2.17B719.93M249.84M1.22B-415.05M-
Financing Cash Flow58.03M-122.44M99.73M-16.64M5.49B-748.60M-421.78M-552.09M-26.57M809.89M274.22M564.47M-1.62B-234.33M2.51B-501.08M329.56M-1.20B-2.14B-
Capital Expenditure10.71M11.95M10.81M54.91M35.93M134.16M237.55M293.98M167.62M168.85M359.54M576.13M535.01M362.08M212.49M193.86M222.42M444.88M202.77M121.10M
Free Cash Flow60.95M1.90M29.32M300.89M318.93M1.27B236.34M126.99M745.18M724.86M-13.46M-983.25M132.86M-589.68M-175.21M-200.49M-979.03M-46.66M1.99B1.59B
Dividends Paid10.80M59.39M19.52M67.58M5.49M800.20M480.12M480.19M262.57M292.27M541.44M444.58M255.14M342.51M224.50M220.09M51.36M425.89M159.90M430.81M
FCF to OCF85.06%13.69%73.06%84.57%89.87%90.45%49.87%30.17%81.64%81.11%-3.89%241.51%19.89%259.08%-469.93%3024.29%129.40%-11.72%90.76%92.93%
Dividend Paid to FCF17.72%3132.71%66.59%22.46%1.72%62.96%203.15%378.12%35.24%40.32%-4021.37%-45.22%192.04%-58.08%-128.13%-109.78%-5.25%-912.71%8.03%27.06%

Earnings

Report DateJun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Apr 30, 2018Jul 30, 2018Oct 29, 2018Feb 27, 2019Apr 29, 2019Oct 29, 2019Feb 28, 2020Apr 29, 2020Aug 28, 2020Oct 29, 2020Mar 29, 2021Apr 28, 2021Aug 26, 2021Oct 27, 2021Mar 30, 2022Apr 29, 2022Aug 29, 2022Oct 28, 2022Mar 29, 2023Apr 28, 2023Aug 30, 2023Oct 30, 2023Jan 10, 2024Apr 29, 2024Sep 2, 2024Oct 30, 2024Apr 25, 2025Sep 1, 2025Oct 31, 2025Mar 30, 2026Apr 30, 2026Aug 31, 2026
EPS Estimate---------------------------------------0.110.130.17---------------------
EPS Actual1.460.880.650.380.260.190.140.220.200.190.180.170.140.050.030.090.050.140.140.230.110.180.200.240.050.030.07-0.010.020.040.060.030.140.170.130.410.170.310.210.260.070.210.100.130.08-0.150.160.190.100.050.050.040.01-0.630.110.350.080.110.180.09-0.140.130.06
Surprise---------------------------------------136.36%-46.15%23.53%---------------------
Timing-------------------------------Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-market-Pre-market------

Key Statistics & Ratios

Market Cap14.45B
Enterprise Value12.34B
Trailing P/E70.36
Forward P/E24.04
PEG Ratio0.00
Price / Sales2.76
Price / Book1.20
EPS0.14
Book Value8.13
Revenue (TTM)5.24B
Gross Profit (TTM)1.75B
EBITDA873.21M
Profit Margin3.87%
Operating Margin9.70%
Return on Equity1.62%
Return on Assets2.08%
Shares Outstanding1.25B
Shares Float411.03M
Beta0.28
Dividend Yield1.51%
Dividend Rate0.15
Payout Ratio104.84%

Dividends

20261×
0.14Jun 18, 2026
20251×
0.25Jul 7, 2025
20231×
0.10Jul 18, 2023
20221×
0.04Jul 28, 2022
20211×
0.15Jul 6, 2021
20201×
0.18Jul 1, 2020
20191×
0.10Jul 15, 2019
20181×
0.04Jul 2, 2018
20171×
0.25Jun 28, 2017
20161×
0.38Jun 13, 2016
20151×
0.19Jun 9, 2015
20141×
0.19Jun 9, 2014
20131×
0.38Jun 5, 2013
20121×
0.38May 9, 2012
20111×
1.25Apr 29, 2011

Stock Splits

  • Jun 13, 201616:10
  • Apr 29, 201120:10